Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06297161 · ClinicalTrials.gov registry record
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
A clinical trial of Chronic Leukemia Myelogenous, sponsored by Pfizer.
- Active
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT06297161: Active study of Chronic Leukemia Myelogenous, sponsored by Pfizer.
NCT06297161 is a study of Chronic Leukemia Myelogenous that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 600 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06297161, a study of Chronic Leukemia Myelogenous, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to look at how safe and effective is bosulif in routine clinical practice. This study is seeking for participants who are: * Adult Patients who are just confirmed to have Chronic Myeloid Leukemia (CML) defined in Local Product Document (LPD). CML is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. LPD explains what a medicine's benefits and problems are. LPD also explains how to use the medicine correctly in Korea. * willing to take part in the study after being informed about the study. All participants in this study will receive bosulif. All participants who have entered this study should meet the usual prescribing criteria for bosulif as per the LPD. The participants will be treated with bosulif under routine clinical practice in Korea. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective. In this study all treatment and checking of the patients will be done as per the study doctor. The study can be performed in Korean health care centers where bosulif is prescribed to treat CML after the patients have agreed to take part in the study.
Conditions Studied
Interventions
- DRUG Bosulif
Study Locations (1)
New York
- Pfizer New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-01-20 |
| Est. Completion | 2028-06-01 |
What the registry record for NCT06297161 still lists
NCT06297161 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Chronic Leukemia Myelogenous appearing as the primary indexed condition, and to 1 intervention - of which Bosulif is the first listed.
NCT06297161 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06297161 about?
NCT06297161 is a clinical study titled "A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).". The purpose of this study is to look at how safe and effective is bosulif in routine clinical practice. This study is seeking for participants who are: * Adult Patients who are just confirmed to have Chronic Myeloid Leukemia (CML) defined in Local Product Document (LPD). CML is a type of cancer th...
What is the current status of trial NCT06297161?
This trial is currently active not recruiting. The enrollment target is 600 participants. The study started on 2025-01-20. Estimated completion is 2028-06-01.
What conditions does trial NCT06297161 study?
This clinical trial studies the following conditions: Chronic Leukemia Myelogenous.
What interventions are being tested in trial NCT06297161?
The interventions under investigation include: Bosulif (DRUG).
Who is sponsoring clinical trial NCT06297161?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06297161 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI